文献速递系统性红斑狼疮

靶向T细胞的IL-2/TGFβ纳米颗粒诱导CD4+与CD8+ Treg抑制小鼠狼疮

Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.
PubMed 文献 · Arthritis Rheumatol · 2019-03-05

本研究构建包裹IL-2与TGFβ、表面包被抗CD2/CD4抗体的PLGA纳米颗粒,在DBA/2 T细胞转移诱导的BDF1狼疮小鼠中评估其扩增Treg及抑制自身免疫的效果。结果显示该纳米颗粒可同时扩增CD4+与CD8+ FoxP3+ Treg细胞,显著抑制抗双链DNA抗体产生并减轻肾脏病变。

要点

  • 抗CD2/CD4抗体包被的IL-2/TGFβ纳米颗粒可在体外诱导CD4+与CD8+ FoxP3+ Treg细胞
  • 该纳米颗粒在狼疮小鼠中扩增Treg、抑制抗DNA抗体并减轻肾脏病变
  • 为Treg功能受损伴IL-2缺乏的自身免疫病提供潜在治疗思路

核心结论

  • 靶向T细胞的PLGA纳米颗粒同时包裹IL-2与TGFβ,可在体内扩增CD4+与CD8+ Treg细胞并抑制小鼠狼疮样疾病。

研究设计与样本

  • 研究为动物实验:将包裹IL-2与TGFβ的PLGA纳米颗粒包被抗CD2/CD4抗体,给予经DBA/2 T细胞转移诱导狼疮样病的BDF1小鼠。
  • 外周Treg频率用流式细胞术离体监测,血清抗双链DNA抗体用酶联免疫吸附试验测定,肾病以蛋白尿或肾脏组织病理特征定义。

主要发现

  • 抗CD2/CD4抗体包被、包裹IL-2与TGFβ的纳米颗粒在体外诱导CD4+与CD8+ FoxP3+ Treg细胞,未包被者无此作用。
  • 在无狼疮小鼠中确定扩增CD4+与CD8+ Treg细胞的最佳给药方案,随后在狼疮BDF1小鼠中测试。
  • 给予该纳米颗粒后CD4+与CD8+ Treg细胞扩增、抗DNA抗体产生明显受抑、肾脏病变减轻。

关键数值与推荐

  • 体外诱导CD4+与CD8+ FoxP3+ Treg细胞仅见于抗CD2/CD4抗体包被的IL-2/TGFβ纳米颗粒,未包被颗粒无此效应。

临床怎么用

  • 提示通过靶向T细胞的纳米颗粒在体内扩增Treg并抑制致病性免疫反应,可能成为SLE等Treg功能受损伴IL-2缺乏疾病的潜在治疗策略。

局限性

  • 证据来自小鼠狼疮样模型,尚未在人类SLE中验证疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a nanoparticle (NP) platform that can expand both CD4+ and CD8+ Treg cells in vivo for the suppression of autoimmune responses in systemic lupus erythematosus (SLE). METHODS: Poly(lactic-co-glycolic acid) (PLGA) NPs encapsulating interleukin-2 (IL-2) and transforming growth factor β (TGFβ) were coated with anti-CD2/CD4 antibodies and administered to mice with lupus-like disease induced by the transfer of DBA/2 T cells into (C57BL/6 × DBA/2)F1 (BDF1) mice. The peripheral frequency of Treg cells was monitored ex vivo by flow cytometry. Disease progression was assessed by measuring serum anti-double-stranded DNA antibody levels by enzyme-linked immunosorbent assay. Kidney disease was defined as the presence of proteinuria or renal histopathologic features. RESULTS: Anti-CD2/CD4 antibody-coated, but not noncoated, NPs encapsulating IL-2 and TGFβ induced CD4+ and CD8+ FoxP3+ Treg cells in vitro. The optimal dosing regimen of NPs for expansion of CD4+ and CD8+ Treg cells was determined in in vivo studies in mice without lupus and then tested in BDF1 mice with lupus. The administration of anti-CD2/CD4 antibody-coated NPs encapsulating IL-2 and TGFβ resulted in the expansion of CD4+ and CD8+ Treg cells, a marked suppression of anti-DNA antibody production, and reduced renal disease. CONCLUSION: This study shows for the first time that T cell-targeted PLGA NPs encapsulating IL-2 and TGFβ can expand both CD4+ and CD8+ Treg cells in vivo and suppress murine lupus. This approach, which enables the expansion of Treg cells in vivo and inhibits pathogenic immune responses in SLE, could represent a potential new therapeutic modality in autoimmune conditions characterized by impaired Treg cell function associated with IL-2 deficiency.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Horwitz DA, Bickerton S, Koss M, et al. Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β. Arthritis Rheumatol. 2019. PMID: 30407752. doi:10.1002/art.40773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。